戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 genous nitric oxide donor), and verapamil (a calcium channel blocker).
2 orable outcomes when randomized to receive a calcium channel blocker.
3        The fourth compound, suloctidil, is a calcium channel blocker.
4 alcium channel blocker or ACE inhibitor plus calcium channel blocker.
5 ist, and 200 nM omega-agatoxin IVA, a P-type calcium channel blocker.
6 concomitantly treated with cyclosporin and a calcium channel blocker.
7 roup, but substituted a beta blocker for the calcium-channel blocker.
8 patients already receiving a beta blocker or calcium-channel blocker.
9 ular block, and those using beta-blockers or calcium channel blockers.
10 e intake of CsA, which might be abrogated by calcium channel blockers.
11 altered in the presence of L-, R- and T-type calcium channel blockers.
12 mpared with patients who have never received calcium channel blockers.
13 ct would be stronger among persons not using calcium channel blockers.
14 phospholipid translocase and is inhibited by calcium channel blockers.
15 um by cobalt and was slowed by more specific calcium channel blockers.
16 rtate (NMDA) receptor antagonist MK 801, and calcium channel blockers.
17 utamate receptor antagonists, and sodium and calcium channel blockers.
18 alcium spikes, blocked by cadmium and L-type calcium channel blockers.
19 nt for differential likelihoods of receiving calcium channel blockers.
20 rdiovascular risks of magnesium sulphate and calcium channel blockers.
21  was activated by voltage and was blocked by calcium channel blockers.
22  potent, selective, brain-penetrating T-type calcium channel blockers.
23  brain penetrant and selective triple T-type calcium channel blockers.
24 ent, selective, and brain-penetrating T-type calcium channel blockers.
25 ement for use of statins, beta-blockers, and calcium channel blockers.
26 d with a beta-blocker or non-dihydropyridine calcium channel blockers.
27  by SOC inhibitors, but not by voltage-gated calcium channel blockers.
28 received verapamil to evaluate the effect of calcium channel blockers.
29 ith sepsis were analyzed, 18.6% of whom used calcium channel blockers.
30 ted a mechanism of action similar to that of calcium channel blockers.
31 ding concurrent use of CYP3A4 inhibitors and calcium-channel blockers.
32 ual variation in SBP was reduced the most by calcium-channel blockers (0.76, 0.67-0.85, p<0.0001).
33 CTs (91%) of diuretics, 5 of 7 RCTs (71%) of calcium channel blockers, 3 of 3 RCTs (100%) of antiplat
34  (-5.76 mm Hg [95% CI -10.28 to -1.23]) or a calcium-channel blocker (-5.13 mm Hg, [-9.47 to -0.79])
35 ngiotensin-receptor blockers, beta-blockers, calcium channel blockers); (5) Most patients with hypert
36  The most commonly used medication class was calcium-channel blockers (55.2%, 55.0-55.4).
37 0.76; 95% confidence interval=0.74-0.78) and calcium channel blockers (adjusted hazard ratio=0.93; 95
38                                 Overdoses of calcium channel blocker agents result in hyperglycemia,
39 ergic blocker (beta-blocker) alone in 24%, a calcium channel blocker alone in 17%, digoxin alone in 1
40                                            A calcium channel blocker also mimicked NGF treatment.
41                         Additionally, use of calcium channel blocker also shows a significant associa
42       Inhibition of Ca(2+) mobilization with calcium channel blockers also inhibits Ang-2 release.
43 tensin-II-receptor blocker irbesartan or the calcium-channel blocker amlodipine slows the progression
44 zyme inhibitor (ramipril), a dihydropyridine calcium channel blocker (amlodipine) or a beta-blocker (
45  or azithromycin (n = 94,083) while taking a calcium-channel blocker (amlodipine, felodipine, nifedip
46 l 2.5-10 mg/d; n = 436) or a dihydropyridine calcium channel blocker, (amlodipine 5-10 mg/d; n = 217)
47  original trials used 3 different statins, a calcium-channel blocker, an angiotensin-converting enzym
48   For primary prevention, we used aspirin, a calcium-channel blocker, an angiotensin-converting-enzym
49 effects of incident diabetes associated with calcium channel blocker and angiotensin-converting enzym
50 16%, a beta-blocker and digoxin in 14%, or a calcium channel blocker and digoxin in 14% of patients.
51 e depolarization was slightly inhibited by a calcium channel blocker and markedly inhibited by a Na(+
52             It was the first clinically used calcium channel blocker and remains in clinical use, alt
53 ented with a K(ATP) channel opener but not a calcium channel blocker and the other potentially arisin
54            The other 2 agents should include calcium channel blockers and angiotensin-converting enzy
55 f cases, VR-PAH has a pronounced response to calcium channel blockers and better survival than vasodi
56 ltures of human kidney epithelial cells with calcium channel blockers and by lowering extracellular c
57                                              Calcium channel blockers and calmodulin inhibitors added
58                                              Calcium channel blockers and calmodulin inhibitors incre
59                                              Calcium channel blockers and hydrochlorothiazide are imp
60 tients with DM were more commonly prescribed calcium channel blockers and long-acting nitrates at dis
61 e reveals inverse correlation between use of calcium channel blockers and lung cancer diagnosis.
62                                              Calcium channel blockers and renin-angiotensin system in
63 termine the association between prior use of calcium channel blockers and the outcome of patients adm
64 rug class use between cases and controls for calcium channel blockers and thiazides was noted.
65                                          For calcium channel blockers and thiazides, the matched odds
66                    Diuretics are superior to calcium channel blockers and, at least in the short term
67                      The opposite effects of calcium-channel blockers and beta blockers on variabilit
68 nsion, nonsteroidal anti-inflammatory drugs, calcium channel blockers, and alcohol, but not for diabe
69 ent for known antipsychotic drugs, selective calcium channel blockers, and antiepileptics.
70 f defective mitochondria, kinase inhibitors, calcium channel blockers, and approaches that interfere
71 sed by the antiseizure medication phenytoin, calcium channel blockers, and ciclosporin.
72 thmics), versus rate control (beta-blockers, calcium channel blockers, and digoxin) treatment strateg
73 olled in the groups receiving beta-blockers, calcium channel blockers, and digoxin, respectively.
74 blockers, beta-blockers, thiazide diuretics, calcium channel blockers, and metformin.
75                     Prostaglandin analogues, calcium channel blockers, and oral corticosteroids have
76 which is structurally related to therapeutic calcium channel blockers, and that a natural coding-regi
77 rate-control treatment with beta-blockers or calcium channel blockers, and the use of beta-blockers w
78  inhibitors, angiotensin II type 1 blockers, calcium channel blockers, and thiazolidinediones have a
79  inhibitors, angiotensin II type 1 blockers, calcium channel blockers, and thiazolidinediones justifi
80 ons were sensitive to membrane potential and calcium channel blockers, and were potentiated by niflum
81            Commonly used medications include calcium channel blockers, angiotensin receptor blockers
82 ated included beta-blockers, ACE inhibitors, calcium channel blockers, angiotensin receptor blockers,
83                                              Calcium channel blockers are among the most commonly use
84 ce, the roles of gene therapy, hepcidin, and calcium channel blockers are being actively investigated
85                  Conversely, the benefits of calcium channel blockers are increasingly recognized.
86                              Dihydropyridine calcium channel blockers are unlikely to have a clinical
87                                              Calcium-channel blockers are grouped under class IV.
88                                High doses of calcium-channel blockers are indicated only in the minor
89 included all published trials concluded that calcium-channel blockers are inferior to other classes o
90                                              Calcium-channel blockers are metabolized by the cytochro
91                            beta-Blockers and calcium-channel blockers are more effective than placebo
92            These findings support the use of calcium channel blockers as a strategy to minimize the n
93 he use of thiazide diuretics and long-acting calcium channel blockers as first-line therapy to treat
94 is assay, we identified fendiline, an L-type calcium channel blocker, as a specific inhibitor of K-Ra
95 this study further support an association of calcium channel blockers, as well as thiazides, with CEE
96  angiotensin-converting enzyme inhibitors or calcium channel blockers at least once during the observ
97  use, although it has been eclipsed by other calcium channel blockers because of its short half-life
98 ication (beta = 0.75; P = .04), specifically calcium channel blockers (beta = -1.02; P < .001), was s
99                           Polytherapy with a calcium channel blocker, beta-blocker, or angiotensin-co
100  compared with pharmacy records for statins, calcium channel blockers, beta-blockers, and bisphosphon
101      Suppression of VA may be achieved using calcium-channel blockers, beta-adrenergic blockers, and
102                     The effects of nitrates, calcium-channel blockers, beta-blockers, and statins on
103  of diabetes, or use of aspirin, statins, or calcium channel blockers between the 2 groups.
104 edium contains nitrendipine, a voltage-gated calcium channel blocker, but fails to occur when applica
105 uld be terminated by nitrendipine, an l-type calcium channel blocker, but not by the Na channel block
106 ivated cation channels but was halved by the calcium channel blocker cadmium and abolished by tetrodo
107                            The voltage-gated calcium channel blocker cadmium chloride did not alter t
108 neurons was not altered by the voltage-gated calcium channel blocker cadmium chloride that blocks bot
109 gic mEPSC was unaltered by the voltage-gated calcium channel blocker cadmium, and was abolished by th
110 y tachykinin neuropeptide, voltage-sensitive calcium channel blocker cadmium, or antioxidants DTT and
111          Oscillations were unaffected by the calcium channel blockers cadmium and nickel and by block
112            Experimental studies suggest that calcium channel blockers can improve sepsis outcome.
113                                              Calcium channel blockers (CCB) are widely prescribed ant
114 gen tension, inhaled nitric oxide (iNO), and calcium channel blockers (CCB) in 10 patients with BPD w
115                               Treatment with calcium channel blockers (CCB), proven to be beneficial
116 ptor (MR) antagonist in vitro potency and no calcium channel-blocker (CCB) activity.
117 dult patients with favorable prognosis using calcium-channel blocker (CCB) therapy.
118 ), ACE inhibitor (1618 of 22,941, or 7.05%), calcium-channel blocker (CCB, 2791 of 38,607, or 7.23%),
119 crolimus while controlling for the effect of calcium channel blockers (CCBs) and supragingival plaque
120                                              Calcium channel blockers (CCBs) are prescribed to patien
121 cancer risk associated with long-term use of calcium channel blockers (CCBs) or angiotensin-convertin
122                             The potential of calcium channel blockers (CCBs) to induce gingival enlar
123        Little is known about associations of calcium channel blockers (CCBs) with outcomes in patient
124 iotensin-converting enzyme (ACE) inhibitors, calcium channel blockers (CCBs), alpha-blockers, and ang
125 450 (CYP3A4) pathway, which also metabolizes calcium channel blockers (CCBs).
126 ing-enzyme inhibitors [ACEi], beta blockers, calcium-channel blockers [CCBs], or diuretics) with foll
127 ccepted mechanism of action of nifedipine, a calcium-channel blocker clinically used in patients with
128                  Among older adults taking a calcium-channel blocker, concurrent use of clarithromyci
129                   Moreover, embryos grown in calcium channel blocker-containing medium had hearts tha
130                        Fatty acid loading or calcium channel blockers could decrease myocardial (18)F
131 nd burst firing, and selective triple T-type calcium channel blockers could offer a new way to treat
132 control studies suggest that dihydropyridine calcium channel blockers (DiCCBs) may protect against Pa
133  or stroke, diuretics plus ACE inhibitors or calcium channel blockers did not differ from diuretics p
134                      Other classes of L-type calcium channel blockers did not mislocalize K-Ras, sugg
135 trials have failed to show conclusively that calcium-channel blockers differ from other antihypertens
136 ttern, we applied the benzothiazepine L-type calcium channel blocker, diltiazem.
137                                    Inorganic calcium channel blockers disclosed that these distinct O
138 CE inhibitors, non-ophthalmic beta blockers, calcium channel blockers, diuretics, and angiotensin rec
139 tor blockers, alpha-blockers, beta-blockers, calcium channel blockers, diuretics, nitrates, statins,
140 s to account for the use of beta-blockers or calcium channel blockers during follow-up did not alter
141                       Ethosuximide, a T-type calcium channel blocker, eliminated busting in lesioned
142 treatments (eg, nitrates, beta blockers, and calcium-channel blockers), emerging anti-angina treatmen
143                                         Most calcium channel blockers exhibit state-dependence (i.e.,
144    Autoantibodies, vascular features, use of calcium channel blockers, extent of pulmonary function,
145 (ATP) channel opener pinacidil (n=6) and the calcium channel blocker flunarizine (n=6).
146 X-sensitive sodium currents and a mixture of calcium channel blockers for calcium currents) and ionic
147                 Nevertheless, the utility of calcium channel blockers for heart disease is limited be
148  the gabapentinoids for neuropathic pain and calcium channel blockers for otherwise intractable pain
149 coding insect specific sodium, potassium and calcium channel blockers for their ability to improve th
150         Women treated with a diuretic plus a calcium channel blocker had an 85% greater risk of CVD d
151                            Voltage-dependent calcium channel blockers had little effect on the initia
152 or responses to ketamine, whereas the L-type calcium-channel blocker had no significant effects on re
153                        Nimodipine, an L-type calcium channel blocker has been shown to reduce iron-in
154                                       Use of calcium channel blockers has been found to improve sepsi
155 We have shown previously that prenylamine, a calcium channel blocker, has potent local anesthetic act
156                                           As calcium channel blockers have been safely used in clinic
157 ntal studies, and in a few clinical studies, calcium channel blockers have been shown to ameliorate s
158                   Consistent with this, many calcium channel blockers have been shown to be neuroprot
159                Oxygen radical scavengers and calcium channel blockers have been shown to enhance func
160 .33; 95% confidence interval, 1.13 to 1.57), calcium channel blockers (HR, 1.57; 95% confidence inter
161 ontrolling anginal symptoms (Dihydropyridine calcium channel blockers if already on a beta-blocking a
162 y on a beta-blocking agent and rate-limiting calcium channel blockers if beta blockers are contraindi
163  data support the use of inotropic agents or calcium channel blockers in heart failure.
164 ective than beta-blockers or dihydropyridine calcium channel blockers in slowing GFR decline.
165 ngiotensin-converting enzyme inhibitors, and calcium channel blockers in the treatment groups was sim
166 rvational data to suggest a central role for calcium channel blockers in the treatment of microvascul
167 tory drugs to 100% for avoiding short-acting calcium-channel blockers in patients with heart failure
168 ished by omitting Na+ or by applying peptide calcium channel blockers, indicating that nAChRs trigger
169 econtamination following a potentially toxic calcium channel blocker ingestion (1D); 2) as first-line
170           We were surprised to discover that calcium channel blockers inhibited TXNIP expression in I
171 re, pretreatment of cells with nifedipine, a calcium channel blocker, inhibited vanadium-induced NFAT
172 hod for developing novel genetically encoded calcium channel blockers inspired by Rem, a small G-prot
173  correlate directly with the severity of the calcium channel blocker intoxication.
174     This study determines whether the use of calcium channel blockers is associated with a decreased
175                                   The fungal calcium channel blocker KP4 inhibited the [Ca(2+)](c) re
176 leakage were inhibited in RPS2 plants by the calcium channel blocker LaCl(3), highly correlating thes
177                             By contrast, the calcium-channel blocker LaCl3 suppressed the increase in
178  of extracellular calcium or addition of the calcium channel blocker lanthanum (0.5 mM) inhibited the
179 otensin II receptor blockers, beta-blockers, calcium channel blockers, loop diuretics, selective sero
180 tudies we have examined the effects of a new calcium channel blocker, LY393615 ((N-Butyl-[5,5-bis-(4-
181 resent studies we have reported that a novel calcium channel blocker, LY393615, with good bioavailabi
182                         The long-term use of calcium channel blockers may be protective, but newer ag
183                 Moreover, antiepileptics and calcium channel blockers may provide repurposing opportu
184 ng from both a KATP channel activation and a calcium channel blocker mechanism.
185  Amlodipine was the most commonly prescribed calcium-channel blocker (more than 50% of patients).
186 with endothelin receptor antagonist (n=2) or calcium channel blocker (n=1).
187 nsin-converting enzyme inhibitors (n = 437), calcium-channel blockers (n = 223), diuretics (n = 226),
188  reduced by 5-HT, and fully abolished by the calcium channel blocker nickel.
189            Although the L-type voltage-gated calcium channel blocker nifedipine did not suppress calc
190 ed calcium entry blocked DIR, but the L-type calcium channel blocker nifedipine did not.
191 nnel agonist Bay K 8644 and inhibited by the calcium channel blocker nifedipine in a dose-dependent m
192 ATP)) channel opener diazoxide or the l-type calcium channel blocker nifedipine mimicked the effect o
193  of CHO or THP-1 (macrophage) cells with the calcium channel blocker nifedipine prevented 25-hydroxyc
194                                          The calcium channel blocker nifedipine reduced, and the sarc
195  primary target is another channel, e.g. the calcium channel blocker nifedipine, the sodium channel b
196           First, we observed that the L-type calcium channel blockers nifedipine and verapamil effect
197 ium release, and the presence of impermeable calcium channel blockers nifedipine, SKF96365, or LaCl3,
198  compare the effectiveness and safety of the calcium-channel blocker nifedipine and the oxytocin inhi
199                             Oxidation of the calcium-channel blocker nifedipine is measured using UV-
200 ceptor blockers (phentolamine, labetalol), a calcium channel blocker (nifedipine), and splanchnic vas
201                                   The L-type calcium channel blocker, nifedipine, significantly atten
202              This effect was mimicked by the calcium channel blocker, nifedipine.
203 ory reactivation by the L-type voltage-gated calcium channel blocker nimodipine interferes with the a
204                                   The L-type calcium channel blockers nimodipine and nifedipine aboli
205 +) but not by Mg(2+) or the classical l-type calcium channel blocker, nitrendipine.
206 uced in patients receiving CsA paralleled by calcium channel blockers nor significantly reduced in pa
207 ination with digoxin, or non-dihydropyridine calcium-channel blockers (not in heart failure) effectiv
208 s study was undertaken to investigate L-type calcium channel blockers of the dihydropyridine class fo
209 oprotective role for centrally acting L-type calcium channel blockers of the dihydropyridine class in
210                                              Calcium channel blockers of the phenylalkylamine family
211 el of alanine mutants of the insect-specific calcium channel blocker omega-atracotoxin-Hv1a.
212 ed by targeted delivery of the voltage-gated calcium channel blocker omega-conotoxin GVIA.
213 ot suppress calcium oscillations, the N-type calcium channel blocker omega-conotoxin inhibited this s
214         The effects of enzyme inhibitors and calcium channel blockers on the actions of the NO donor
215 ts should continue to take beta-blockers and calcium channel blockers on the day of surgery.
216 ients were either receiving beta-blockers or calcium-channel blockers on follow-up.
217 ffect of nilvadipine, a dihydropyridine-type calcium channel blocker, on Abeta induced vasoconstricti
218  plus either ACE inhibitor, beta-blocker, or calcium channel blocker or ACE inhibitor plus calcium ch
219 population, including those with diabetes, a calcium channel blocker or thiazide-type diuretic is rec
220 oices should be a long-acting diuretic and a calcium-channel blocker or a beta-blocker, respectively.
221                               Patients given calcium-channel blockers or alpha blockers had a 65% (ab
222    All randomised controlled trials in which calcium-channel blockers or alpha blockers were used to
223 se all randomised controlled trials in which calcium-channel blockers or alpha blockers were used to
224                                              Calcium channel blockers (OR = 0.5, 95% CI: 0.2, 0.9) an
225 ]; P = .002), and the use of dihydropyridine calcium channel blockers (OR, 9.24 [95% CI, 1.35-63.23];
226 therapy with an ACE inhibitor, beta-blocker, calcium channel blocker, or diuretic, and 4493 (23%) wer
227 yme inhibitor, angiotensin receptor blocker, calcium channel blocker, or thiazide-type diuretic in th
228 e inhibitors, angiotensin-receptor blockers, calcium channel blockers, or beta blockers) was signific
229         No adequate trials of dexamethasone, calcium channel blockers, or magnesium sulphate have yet
230  of medications classified as beta blockers, calcium channel blockers, or psychotropics.
231 ngiotensin-receptor blockers, beta blockers, calcium-channel blockers, or direct renin inhibitors (pr
232 ngiotensin receptor blockers, beta blockers, calcium channel blockers, other BP medications, aspirin,
233 eding index (P=0.001) and concomitant use of calcium channel blockers (P=0.029); in CsA and Tcr group
234 le sex, diabetes status, insulin use, use of calcium channel blocker, panendoscopic examination, hype
235 no history of CVD, a 2-drug-class regimen of calcium channel blockers plus diuretics was associated w
236 rovide a management approach for adults with calcium channel blocker poisoning.
237     In our primary analyses, we excluded all calcium channel blocker prescriptions 2 years before ind
238 Analyses of some randomised trials show that calcium-channel blockers reduce the risk of stroke more
239 gents, including beta-blockers, nitrates and calcium channel blockers, remain the mainstay in the pre
240 ial treatment of systemic corticosteroid and calcium channel blocker, remarkable improvement was noti
241                               Replacement of calcium channel blockers resulted in the largest potenti
242 lcium influx was blocked by the nonselective calcium channel blockers ruthenium red, 1-(beta-[3-(4-me
243  statins, histamine H2-receptor blockers, or calcium-channel blockers seems to prevent Alzheimer's di
244 diabetic mice with cilnidipine, an N-/L-type calcium channel blocker, showed a reduction in albuminur
245 ore severe digital tip ulcers, but they used calcium channel blockers significantly less frequently (
246 ith cyclosporin A and concomitantly taking a calcium channel blocker since transplant were entered in
247                           Treatment with the calcium channel blocker SK&F 96365 inhibited translocati
248 ibited by the calcium chelator BAPTA-AM, the calcium channel blocker SK&F 96365, and calpeptin, an in
249 x was also inhibited by omega-agatoxin-TK, a calcium channel blocker specific for Ca(v)2.1 channels.
250                             First-generation calcium channel blockers such as verapamil are a widely
251                        On subgroup analysis, calcium channel blockers tend to be more beneficial to p
252 veal a universal method for developing novel calcium channel blockers that may be extended to develop
253  gene transfer of Gem functions as a genetic calcium channel blocker, the local application of which
254  In this national cohort study, preadmission calcium channel blocker therapy before sepsis developmen
255                    Patients who responded to calcium channel blocker therapy had metabolic profiles s
256  patients showing long-term improvement with calcium channel-blocker therapy.
257 reports about 19 diverse treatments, such as calcium-channel-blocker therapy for coronary artery dise
258 phenylalkylamine (PAA), and it was the first calcium channel blocker to be used clinically.
259  of hearts with diltiazem, a specific L-type calcium channel blocker, to eliminate the involvement of
260 commendations for the stepwise management of calcium channel blocker toxicity.
261 ients with sepsis, of which, 19,742 received calcium channel blocker treatments prior to the admissio
262                      The association between calcium channel blocker use and sepsis outcome was deter
263 test the association between dihydropyridine calcium channel blocker use and the time to important mi
264                                        Prior calcium channel blocker use is associated with reduced m
265                                   Concurrent calcium channel blocker use minimizes or negates the inv
266                                        Prior calcium channel blocker use was not associated with chan
267  found no evidence of effect modification by calcium channel blocker use, possibly because of modest
268 ations and to examine effect modification by calcium channel blocker use, using linear regression and
269 t smoking, prior cardiovascular disease, and calcium channel blocker use.
270 ministration of artemether and nimodipine, a calcium channel blocker used to treat postsubarachnoid h
271 nsidering large baseline differences between calcium channel blocker users and nonusers, a propensity
272 hrombin levels, which were less decreased in calcium channel blocker users.
273 ensity-matched cohort (20.2% vs 32.9% in non-calcium channel blockers users; p = 0.009) and in multiv
274                In sharp contrast, the L-type calcium channel blocker verapamil markedly decreased S1P
275 ivo, we administered the clinically approved calcium channel blocker verapamil to obese mice.
276 sed in combination with 2 broadly prescribed calcium channel blockers (verapamil ER and diltiazem ER)
277                                              Calcium channel blockers (verapamil, lanthanum) can also
278 erindividual variation in SBP was reduced by calcium-channel blockers (VR 0.81, 95% CI 0.76-0.86, p<0
279                             Monotherapy with calcium channel blockers vs diuretics was associated wit
280  ratios for diabetes, insulin use and use of calcium channel blocker was 1.133 (1.074, 1.195), 1.414
281                                       Use of calcium channel blocker was associated with a reduced 30
282 concomitantly treated with cyclosporin and a calcium channel blocker was associated with functional p
283                                 Prior use of calcium channel blockers was associated with improved 30
284 onferroni correction was applied, the use of calcium channel blockers was most strongly associated wi
285 ribing clarithromycin vs azithromycin with a calcium-channel blocker was associated with a higher ris
286 iew to creating a focally applicable genetic calcium channel blocker, we overexpressed the ras-relate
287 -reported use of statins, beta-blockers, and calcium channel blockers were all 95% or greater.
288    In addition, the effects of potassium and calcium channel blockers were also tested for comparison
289                  Statins, beta-blockers, and calcium channel blockers were each reported by over 15%
290         For the prevention of heart failure, calcium channel blockers were inferior and diuretics wer
291                                              Calcium channel blockers were superior to other drugs fo
292       Nitroglycerin as needed and a beta- or calcium-channel blocker were allowed.
293 t failure is increased in patients receiving calcium channel blockers when compared with those receiv
294 w that long-term treatment with verapamil, a calcium channel blocker with vasodilator properties, can
295 orming alpha1-subunits can be converted into calcium channel blockers with tunable selectivity, kinet
296                              Nimodipine is a calcium-channel blocker with specific cerebral vasodilat
297  alpha blockers was 1.54 (1.29-1.85) and for calcium-channel blockers with steroids was 1.90 (1.51-2.
298 rst drug (with or without digoxin), 54% with calcium channel blockers (with or without digoxin), and
299 enzyme (ACE) inhibitor and a dihydropyridine calcium-channel blocker would be more effective in reduc
300 holesterol content can be reversed by AbetaP calcium channel blockers Zn2+ and tromethamine.

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top